Knight Therapeutics (OTCMKTS:KHTRF) Trading Up 5.2% – Still a Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares traded up 5.2% during trading on Tuesday . The stock traded as high as $3.80 and last traded at $3.80. 1,403 shares were traded during mid-day trading, a decline of 75% from the average session volume of 5,681 shares. The stock had previously closed at $3.61.

Knight Therapeutics Stock Up 5.2 %

The company has a fifty day moving average of $3.74 and a 200 day moving average of $4.03.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.